Abingdon Health, a developer and manufacturer of rapid tests, it has signed an exclusive manufacturing agreement with BioSure, a UK company specialising in the provision of rapid in-vitro diagnostic testing solutions.

Under the terms of the exclusive agreement, Abingdon will manufacture BioSure’s own lateral flow tests in the field of COVID-19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon’s York and Doncaster sites.

Chris Yates, CEO of Abingdon Health, said: “We are delighted to be supporting BioSure and building on our long—term collaboration with the BioSure team. We are committed to supporting the deployment of these much-needed lateral flow test to the UK and international markets.”

Brigette Bard, CEO of BioSURE, added: “We are thrilled to be continuing to build our portfolio of products with Abingdon. BioSure is committed to delivering British developed tests to the global market and Abingdon are our ideal partner to manufacture our world-leading products.”